280752-78-5

Usage

Uses

Used in Pharmaceutical Development:
(6-bromo-2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methanol is used as an intermediate in the pharmaceutical industry for the synthesis of various drugs. Its unique chemical structure and reactivity make it a promising candidate for the development of new therapeutic agents.
Used in Agrochemicals:
In the agrochemical industry, (6-bromo-2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methanol is used as a building block for the creation of novel compounds with potential applications in pest control and crop protection. Its chemical properties may contribute to the development of more effective and environmentally friendly agrochemicals.
Used in Specialty Chemicals:
(6-bromo-2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methanol is also utilized in the specialty chemicals sector, where it can be employed in the synthesis of various compounds with specific applications in industries such as plastics, coatings, and adhesives. Its unique structure and reactivity make it a valuable component in the development of innovative materials with tailored properties.
Organic Chemistry Research:
(6-bromo-2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methanol is a subject of interest for researchers in the field of organic chemistry, particularly in drug discovery. Its properties and potential uses make it a valuable compound for exploring new synthetic pathways and developing novel chemical entities with potential applications in various industries.

Upstream product

• 30186-18-6 4'-bromo-2'-hydroxyacetophenone 
• 22532-62-3 4-bromosalicylaldehyde 
• 17345-77-6 1-bromo-3,4-dihydroxybenzene 
• 556-52-5 oxiranyl-methanol 

Downstream Products

• 938457-92-2 6-bromo-2-(4-toluenesulfonyloxymethyl)-2,3-dihydrobenzo[1,4]dioxin 
• 527680-73-5 2-[(benzyloxy)methyl]-6-bromo-2,3-dihydro-1,4-benzodioxine 

Relevant academic research and scientific papers

Enantioselective Access to Chiral 2-Substituted 2,3-Dihydrobenzo[1,4]dioxane Derivatives through Rh-Catalyzed Asymmetric Hydrogenation

Rh-catalyzed asymmetric hydrogenation of various benzo[b][1,4]dioxine derivatives was successfully developed to prepare chiral 2-substituted 2,3-dihydrobenzo[1,4]dioxane derivatives using ZhaoPhos and N-methylation of ZhaoPhos ligands with high yields and excellent enantioselectivities (up to 99% yield, >99% enantiomeric excess (ee), turnover number (TON) = 24 000). Moreover, this asymmetric hydrogenation methodology, as the key step with up to 10 000 TON, was successfully applied to develop highly efficient synthetic routes for the construction of some important biologically active molecules, such as MKC-242, WB4101, BSF-190555, and (R)-doxazosin·HCl.

Design and optimization of 2,3-dihydrobenzo[b][1,4]dioxine propanoic acids as novel GPR40 agonists with improved pharmacokinetic and safety profiles

GPR40 has become a new potential therapeutic target for the treatment of diabetes due to its role in mediating the enhancement of glucose-stimulated insulin secretion in pancreatic β cells with a low risk of hypoglycemia. As an effort to extend the chemical space and identify structurally distinct GPR40 agonists with improved liver safety, a novel series of fused-ring phenyl propanoic acid analogues were designed. Comprehensive structure-activity relationship studies around novel scaffolds were conducted and led to several analogues exhibited potent GPR40 agonistic activities and high selectivity against other fatty acid receptors. Further evaluation of pharmacokinetic (PK) profiles and in vivo efficacy identified compound 40a with excellent PK properties and significant glucose-lowering efficacy during an oral glucose tolerance test. In addition, compound 40a displayed lower hepatobiliary transporter inhibition and favorable druggability. All results indicate that compound 40a is a promising candidate for further development.

BROMODOMAIN INHIBITORS

The present invention relates to substituted heterocyclic derivative compounds, compositions comprising said compounds, and the use of said compounds and compositions for epigenetic regulation by inhibition of bromodomain-mediated recognition of acetyl lysine regions of proteins, such as histones. Said compositions and methods are useful for the treatment of cancer and neoplastic disease.

Synthesis and glycogen phosphorylase inhibitor activity of 2,3-dihydrobenzo[1,4]dioxin derivatives

Novel 5-benzyl and 5-benzylidene-thiazolidine-2,4-diones carrying 2,3-dihydrobenzo[1,4]dioxin pharmacophore were synthesized and their glycogen phosphorylase inhibitor activity was also studied.